<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400517</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-4643</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-4643</secondary_id>
    <secondary_id>CELGENE-CASE-CCF-4643</secondary_id>
    <secondary_id>BRLX-CASE-CCF-4643</secondary_id>
    <nct_id>NCT00400517</nct_id>
  </id_info>
  <brief_title>GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different
      ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by
      blocking blood flow to the tumor. Giving GM-CSF and thalidomide before surgery may make the
      tumor smaller and reduce the amount of normal tissue that needs to be removed.

      PURPOSE: This phase II trial is studying how well giving GM-CSF together with thalidomide
      works in treating patients undergoing surgery for high-risk prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the impact of neoadjuvant sargramostim (GM-CSF) and thalidomide on pathologic
           response (histologic P0, margin positivity, capsular penetration), prostate-specific
           antigen (PSA) response, and other investigational endpoints in patients with high-risk
           prostate cancer undergoing prostatectomy.

        -  Determine the safety and feasibility of GM-CSF and thalidomide.

      OUTLINE: This is an open-label study.

      Patients receive sargramostim (GM-CSF) subcutaneously on days 1, 3, and 5 and oral
      thalidomide on days 1-5 or 1-7 in weeks 1-4. Treatment repeats every 4 weeks for 2 courses in
      the absence of unacceptable toxicity.

      Patients undergo radical prostatectomy with bilateral pelvic lymphadenectomy at week 8 or 9.

      PROJECTED ACCRUAL: A total of 29 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients P0 at Surgery</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pathologic Complete Response is defined as complete eradication of tumor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients With Negative Surgical Margins</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Presence or Absence of prostate cancer tissue at the sites of surgical resection. This is done by reviewing the entire specimen resected at the time or Radical Prostatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate-specific Antigen Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of subjects that achieved a PSA decline while on therapy. Any PSA decline while on treatment, compared with baseline PSA prior to study entry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Clinical Progression</measure>
    <time_frame>32 months</time_frame>
    <description>Time to progression. WIth a median follow up of 32 months (12-51 months), 5 of 26 patients developed biochemical failure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>GM-CSF Injections and Oral Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day</description>
    <arm_group_label>GM-CSF Injections and Oral Thalidomide</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>doses up to 400 mg/day</description>
    <arm_group_label>GM-CSF Injections and Oral Thalidomide</arm_group_label>
    <other_name>THALOMID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>SOC care surgery</description>
    <arm_group_label>GM-CSF Injections and Oral Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>post radical prostatectomy</description>
    <arm_group_label>GM-CSF Injections and Oral Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate meeting any of the following
             criteria for high-risk disease:

               -  Clinical stage II or III (T2b, T2c, or T3 with any grade or prostate-specific
                  antigen [PSA])

               -  Gleason score 7 (4+3 only) or ≥ 8 (any stage or PSA)

               -  Serum PSA ≥ 10 ng/dL (any grade or stage)

               -  Any stage, PSA, or Gleason score with ≥ 35% chance of biochemical failure at 5
                  years based on Kattan's nomogram

          -  No clinical evidence of CNS metastases

          -  No metastatic disease as demonstrated by radiological exam (CT scan, MRI, bone scan,
             x-ray) within 8 weeks of study entry

          -  Appropriate medical candidate for radical prostatectomy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Creatinine ≤ 2.0 mg/dL

          -  Granulocyte count ≥ 1,800/mm³

          -  Platelet count ≥ 100,000/mm³

          -  AST &lt; 3 times upper limit of normal

          -  Bilirubin ≤ 1.5 mg/dL

          -  Fertile patients must use effective contraception during and for 4 weeks after
             completion of study treatment

          -  No active unresolved infection

          -  No pre-existing peripheral neuropathy &gt; grade 1

          -  No known HIV positivity

          -  No other malignancy within the past 5 years except curatively treated basal cell or
             squamous cell carcinoma of the skin or controlled Ta transitional cell carcinoma of
             the bladder

          -  No known contraindication to sargramostim (GM-CSF) or thalidomide

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to the prostate or pelvis

          -  No prior chemotherapy or hormonal therapy for prostate cancer

          -  No parenteral antibiotics within the past 7 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Garcia, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2018</results_first_posted>
  <disposition_first_submitted>April 18, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 19, 2017</disposition_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GM-CSF Injections and Oral Thalidomide</title>
          <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">1 pt w/d consent. 1 pt found to have unresectable dx at time of sx and is exc. in tissue analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GM-CSF Injections and Oral Thalidomide</title>
          <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="44" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients P0 at Surgery</title>
        <description>Pathologic Complete Response is defined as complete eradication of tumor.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Injections and Oral Thalidomide</title>
            <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients P0 at Surgery</title>
          <description>Pathologic Complete Response is defined as complete eradication of tumor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Negative Surgical Margins</title>
        <description>Presence or Absence of prostate cancer tissue at the sites of surgical resection. This is done by reviewing the entire specimen resected at the time or Radical Prostatectomy.</description>
        <time_frame>8 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Injections and Oral Thalidomide</title>
            <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Negative Surgical Margins</title>
          <description>Presence or Absence of prostate cancer tissue at the sites of surgical resection. This is done by reviewing the entire specimen resected at the time or Radical Prostatectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate-specific Antigen Response</title>
        <description>Number of subjects that achieved a PSA decline while on therapy. Any PSA decline while on treatment, compared with baseline PSA prior to study entry.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Injections and Oral Thalidomide</title>
            <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen Response</title>
          <description>Number of subjects that achieved a PSA decline while on therapy. Any PSA decline while on treatment, compared with baseline PSA prior to study entry.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Clinical Progression</title>
        <description>Time to progression. WIth a median follow up of 32 months (12-51 months), 5 of 26 patients developed biochemical failure.</description>
        <time_frame>32 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Injections and Oral Thalidomide</title>
            <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Progression</title>
          <description>Time to progression. WIth a median follow up of 32 months (12-51 months), 5 of 26 patients developed biochemical failure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GM-CSF Injections and Oral Thalidomide</title>
          <description>taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
sargramostim: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
thalidomide: doses up to 400 mg/day
conventional surgery: SOC care surgery
neoadjuvant therapy: post radical prostatectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Solmnolene/Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neropathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jorge Garcia</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>2164447774</phone>
      <email>Garciaj4@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

